TECNIS PureSee IOL clinical data took center stage at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, as Johnson & Johnson [Read More…]
Johnson & Johnson MedTech has announced the European launch of its latest pulsed field ablation innovation, VARIPULSE Pro, designed to enhance procedural efficiency and precision in treating cardiac arrhythmias.
Gilead Sciences has entered into a definitive agreement to acquire Tubulis for up to $5 billion, adding the “best-in-class” TUB-040 asset and a next-generation ADC platform to its growing oncology portfolio.
Amgen has announced successful topline results from its Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA® for Thyroid Eye Disease, offering a new, convenient delivery method.
Thermo Fisher Scientific has unveiled the Gibco CHOvantage GS, a next-generation biologics development platform designed to accelerate timelines to the clinic while ensuring regulatory compliance and scalability.
AstraZeneca announces positive results from the EMERALD-2 Phase III trial, proving that the Imfinzi and Imjudo liver cancer treatment significantly delays disease recurrence in patients following surgery or ablation.
New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.
Eli Lilly has officially received Foundayo FDA approval for orforglipron, the first daily non-peptide oral GLP-1 receptor agonist that offers significant weight loss results without the dietary restrictions of previous oral treatments.
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, signaling a major expansion into the sleep medicine market through innovative orexin receptor agonists.
GSK has secured the Exdensur depemokimab China approval from the NMPA, introducing the first respiratory biologic with a twice-yearly dosing regimen for patients with severe eosinophilic asthma.
